Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast
1. Eli Lilly reported Q3 earnings, beating expectations significantly. 2. Quarterly revenue rose 54% to $17.60 billion, ahead of the $16.02 billion estimate. 3. Mounjaro and Zepbound drove major revenue growth, reflecting strong demand. 4. Eli Lilly raised its annual sales forecast to $63-$63.5 billion. 5. The company plans a $1.2 billion investment in Puerto Rico for manufacturing expansion.